Clinical Trials Logo

Clinical Trial Summary

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.


Clinical Trial Description

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04177316
Study type Observational
Source Chang Gung Memorial Hospital
Contact
Status Completed
Phase
Start date December 1, 2018
Completion date November 15, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06157060 - Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Not yet recruiting NCT04850040 - A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin Phase 2
Not yet recruiting NCT06449846 - Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Completed NCT06294808 - Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Recruiting NCT06003673 - A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC Phase 4
Recruiting NCT05766605 - Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial Phase 3